Correction: Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28‑Joint C‑Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis
Clinical Pharmacokinetics · 2026-08 · 65 (8) · 1273-1274
DOI: 10.1007/s40262-026-01656-y ↗Kurz gefasst
Korrektur in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 10.07.2026. Verfasst von Lei Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi Genzyme, Bridgewater, NJ, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Sanofi Genzyme, Bridgewater, NJ, USA.
- Sanofi Genzyme, Bridgewater, NJ, USA. christine.xu@sanofi.com.
- Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
Zitieren
APA
Ma, L., Xu, C., Paccaly, A., & Kanamaluru, V. (2026). Correction: Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28‑Joint C‑Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis. Clinical Pharmacokinetics, 65(8), 1273-1274. https://doi.org/10.1007/s40262-026-01656-y
Vancouver
Ma L, Xu C, Paccaly A, Kanamaluru V. Correction: Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28‑Joint C‑Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis. Clinical Pharmacokinetics. 2026;65(8):1273-1274. doi:10.1007/s40262-026-01656-y
BibTeX
@article{Ma2026,
author = {Ma, Lei and Xu, Christine and Paccaly, Anne and Kanamaluru, Vanaja},
title = {Correction: Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28‑Joint C‑Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis},
journal = {Clinical Pharmacokinetics},
year = {2026},
volume = {65},
number = {8},
pages = {1273--1274},
doi = {10.1007/s40262-026-01656-y}
}
EUVIMED